ANIK

Anika Therapeutics Inc

ANIK, USA

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

https://www.anika.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ANIK
stock
ANIK

Jobs Data: Why Pimco 15 Year U.S. stock is a strong buy call - July 2025 Price Swings & High Accuracy Trade Alerts moha.gov.vn

Read more →
ANIK
stock
ANIK

Trend Dashboard Flags Anik Industries Limited As Potential Swing Trade - Fundamental Stock Analysis & You’ll Thank Yourself in 6 Months earlytimes.in

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$16

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.94

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-1.59 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.23 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

17.91 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.29

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 73.54% of the total shares of Anika Therapeutics Inc

1.

Trigran Investments Inc

(14.1247%)

since

2025/06/30

2.

BlackRock Inc

(10.5998%)

since

2025/06/30

3.

Caligan Partners LP

(9.9537%)

since

2025/06/30

4.

Vanguard Group Inc

(5.4062%)

since

2025/06/30

5.

Dimensional Fund Advisors, Inc.

(4.3215%)

since

2025/06/30

6.

Opaleye Management Inc

(4.0837%)

since

2025/06/30

7.

BOOTHBAY FUND MANAGEMENT, LLC

(3.6725%)

since

2025/06/30

8.

Renaissance Technologies Corp

(3.6566%)

since

2025/06/30

9.

Alta Fundamental Advisers LLC

(3.1554%)

since

2025/06/30

10.

Capital Management Corp

(2.8356%)

since

2025/06/30

11.

State Street Corp

(2.2497%)

since

2025/06/30

12.

Geode Capital Management, LLC

(2.2278%)

since

2025/06/30

13.

Stonepine Capital Management Llc

(1.3219%)

since

2025/06/30

14.

Millennium Management LLC

(0.9271%)

since

2025/06/30

15.

Charles Schwab Investment Management Inc

(0.9228%)

since

2025/06/30

16.

D. E. Shaw & Co LP

(0.8606%)

since

2025/06/30

17.

Envestnet Asset Management Inc

(0.8419%)

since

2025/06/30

18.

Jacobs Levy Equity Management, Inc.

(0.8277%)

since

2025/06/30

19.

Northern Trust Corp

(0.795%)

since

2025/06/30

20.

Morgan Stanley - Brokerage Accounts

(0.7517%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(4.5)
Quality
Moderate Quality(4.5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.